NORCROSS, Ga., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be participating in the H.C. Wainwright 7th Annual NASH Investor Conference being held virtually on October 24, 2023.

美国乔治亚州诺克罗斯，2023年10月23日（GLOBE NEWSWIRE）-半乳糖凝集素治疗公司（纳斯达克股票代码：GALT）是针对半乳糖凝集素蛋白的治疗药物的领先开发商，今天宣布该公司将参加H.C.Wainwright第7届年度NASH投资者会议实际上于2023年10月24日举行。

Dr. Pol F. Boudes, Galectin Therapeutics’ Chief Medical Officer, will deliver a corporate presentation on Tuesday, October 24, 2023 at 11:30 AM ET. A live webcast of the discussion will be available at this link as well as through the investor relations section of the Company’s website at www.galectintherapeutics.com.About Belapectin Belapectin is a complex carbohydrate drug that targets galectin-3, a critical protein in the pathogenesis of NASH when it has progressed to the liver cirrhosis stage as well as advanced cancers.

Galectin Therapeutics的首席医疗官Pol F.Boudes博士将于2023年10月24日星期二上午11:30发表公司演讲。讨论的实时网络广播将在本链接以及公司网站的投资者关系部分www.galectintherapeutics.com上提供。关于Belapectin Belapectin是一种复杂的碳水化合物药物，靶向半乳糖凝集素-3，这是一种关键蛋白质。NASH发病机制进展为肝硬化阶段以及晚期癌症时。

Galectin-3 is produced by activated macrophages, a key inflammatory cell, and plays a major role in diseases that involve scarring of organs, including fibrotic disorders of the liver, lung, kidney, heart, as well as in the cancerous tumor microenvironment. Belapectin binds to galectin-3 and disrupts its function.

半乳糖凝集素-3由活化的巨噬细胞（一种关键的炎性细胞）产生，并且在涉及器官瘢痕形成的疾病中起主要作用，包括肝，肺，肾，心脏的纤维化疾病以及癌性肿瘤微环境。Belapetin与半乳糖凝集素-3结合并破坏其功能。

Belapectin, because of its unique structure, is also captured by activated macrophages and exerts its activity directly at the source of galectin-3 production. Preclinical data in animals have shown that belapectin has robust treatment effects in reversing liver fibrosis associated with liver cirrhosis, a disease that is characterized by an invasion of activated macrophages into the liver parenchyma.

由于其独特的结构，Belapetin也被活化的巨噬细胞捕获，并直接在半乳糖凝集素-3产生的来源发挥其活性。动物的临床前数据显示，belapectin在逆转与肝硬化相关的肝纤维化方面具有强大的治疗效果，肝硬化是一种以活化的巨噬细胞侵入肝实质为特征的疾病。

A Phase 2 study showed belapectin may prevent the development of esophageal varices in NASH cirrhosis, and these results provide the basis for the conduct of the NAVIGATE trial. The NAVIGATE trial (www.NAVIGATEnash.com), titled “A Sea.

第二阶段的研究表明，belapectin可以预防NASH肝硬化食管静脉曲张的发展，这些结果为NAVIGATE试验的进行提供了基础。NAVIGATE试用版（www.NAVIGATEnash.com），标题为“A Sea”。